Katherine tdm1
WebbA trial of TDM1 after surgery for breast cancer (KATHERINE) Cancer type: Breast cancer Status: Results Phase: Phase 3 This trial looked at a drug called trastuzumab … WebbTrastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study Breast Cancer Res Treat. 2024 Jun;187 (3):759-768. doi: 10.1007/s10549-021-06166-y. Epub 2024 Apr 15. Authors
Katherine tdm1
Did you know?
Webb14 apr. 2024 · The KATHERINE study (NCT01772472) evaluated adjuvant T-DM1 versus trastuzumab in patients with histologically confirmed, centrally confirmed, HER2-positive, nonmetastatic, invasive primary breast cancer [T1–4, N0–3, M0 (excluding T1aN0 and T1bN0)] at presentation, and residual invasive disease detected pathologically in the …
Webb5 dec. 2024 · KATHERINE trial, which compared adjuvant T-DM1 with trastuzumab in patients who had HER2-positive early breast cancer and residual in-vasive cancer at … Webb25 maj 2024 · Background: The Katherine trial has shown that adjuvant T-DM1 improved invasive disease free survival (iDFS) of patients with HER2+ breast cancer who did not achieve a pathological complete response (pCR) with trastuzumab-based neoadjuvant chemotherapy (NAC). However, some subgroups may benefit less from this treatment …
Webb23 maj 2024 · The new approval, announced on May 3, is based on findings from a large clinical trial called KATHERINE that compared T-DM1 with trastuzumab (Herceptin) as … WebbTrastuzumab emtansine, [6] [7] sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1.
Webb5 dec. 2024 · For the primary endpoint in the KATHERINE trial of invasive disease-free survival – defined as freedom from ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral invasive breast cancer, distant recurrence, or death from any cause – T-DM1 was associated with a hazard …
Webb1 sep. 2024 · T-DM1 is comprised of trastuzumab conjugated to emtansine, a microtubule inhibitor. Other microtubule inhibitors, including taxanes and vinca alkaloids, are known radiation sensitizers, potentially increasing the risk radiation-related toxicities including dermatitis and pneumonitis [10]. giggle at the ghostiesWebb26 maj 2024 · 513 Background: The phase 3 KATHERINE (NCT01772472) study, met its primary endpoint by demonstrating significantly improved invasive disease-free survival with adjuvant T-DM1 compared to H in pts with residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy. PROs are reported here. Methods: Eligible … giggle and squid winchesterWebb14 feb. 2024 · Conclusions: Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of … ftc solar austin texasWebb21 jan. 2013 · A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) The safety and scientific validity of this study is the responsibility of the study sponsor and … ftc solar texasWebb6 dec. 2024 · The KATHERINE investigators concluded that among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone. The study was funded by F. … giggle at the ghostlyWebb6 dec. 2024 · The KATHERINE investigators reported at San Antonio Breast Cancer Symposium and published on 5 December 2024 in The New England Journal of … giggle baby carrierWebb17 jan. 2024 · Symptoms to watch for include swelling of the ankles or legs, shortness of breath, cough, or weight gain of more than 5 pounds in less than 24 hours. Lung problems: Kadcyla may cause inflammation of the lungs, which can be life-threatening. Symptoms include trouble breathing, cough, tiredness, and fluid in the lungs. giggle baby clothing